NASDAQ
ALNY
Last Price
US $281.26
KEY FIGURES
MKT CAP
$37.6B
EPS
TTM
$4.34
PEG
TTM
0.03x
P/E
TTM
64.75x
P/S
TTM
8.72x
YIELD
0.00%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
98.29%
Return on equity
ROIC: 19.66%
Valuation History
68.5X
Price to Earnings
EV/EBITDA: 42.7X
Cash flow
Profit margin
49.77%
(FY vs FY)
EBITDA Y/Y
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $281.26
—
Default assumptions
EBITDA Multiple
Fair Value
Market $281.26
-88.53%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Alnylam Pharmaceuticals, Inc. cash flow to debt ratio of 41.00% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.
Financial stability - Healthy cash flow growth.
Alnylam Pharmaceuticals, Inc.'s free cash flow has increased -1.19K% from $-42.59M last year to $465.38M, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
Alnylam Pharmaceuticals, Inc.'s debt to equity ratio is 1.18, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial stability - Healthy debt to equity ratio development.
Alnylam Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 40.89 last year to 1.18 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Alnylam Pharmaceuticals, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Alnylam Pharmaceuticals, Inc.'s interest coverage ratio of 2.66 indicates that earnings with margin can cover interest payments on company debt
Financial stability - Profit margin growth.
Alnylam Pharmaceuticals, Inc.'s profit margin has increased (-208.83%) in the last year from -12.37% to 13.46%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Alnylam Pharmaceuticals, Inc.'s short-term assets of $4.05G exceed its short-term liabilities of $1.47G
Increasing performance - ROA.
Alnylam Pharmaceuticals, Inc.'s return on assets of 11.25% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
Alnylam Pharmaceuticals, Inc.'s return on equity of 98.29%, is higher than 15.00%, indicating good performance
Increasing performance - Earnings quality.
Alnylam Pharmaceuticals, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Decreasing performance - Earnings stability.
Alnylam Pharmaceuticals, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings
Increasing performance - Free cash flow.
Alnylam Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Decreasing performance - FCF yield.
Alnylam Pharmaceuticals, Inc. has a free cash flow yield of 1.24%, which is below the 2.00% threshold, indicating limited cash return relative to market value
Increasing performance - Healthy earnings growth.
Alnylam Pharmaceuticals, Inc.'s yearly earnings has increased -212.79% since last year from $-278.16M to $313.75M, signaling increasing performance
Increasing performance - Healthy revenue growth.
Alnylam Pharmaceuticals, Inc.'s yearly revenue has increased 65.19% since last year from $2.25G to $3.71G, signaling increasing performance
Increasing performance - ROIC.
ROIC 19.66% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Increasing performance - 3-year revenue CAGR.
Alnylam Pharmaceuticals, Inc.'s 3-year revenue CAGR of 52.98% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Alnylam Pharmaceuticals, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Alnylam Pharmaceuticals, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Alnylam Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Alnylam Pharmaceuticals, Inc. has an earnings yield of 1.54%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings
Overvalued - EBITDA valuation.
Alnylam Pharmaceuticals, Inc. is overvalued relative to its fair value price of 32.27 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Alnylam Pharmaceuticals, Inc. has an EV/EBITDA ratio of 58.87x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings
Undervalued - PEG ratio value.
Alnylam Pharmaceuticals, Inc. has a PEG-ratio under 1 which is considered undervalued
Overvalued - P/B ratio.
Alnylam Pharmaceuticals, Inc. has a price-to-book ratio of 34.76x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Overvalued - P/S ratio.
Alnylam Pharmaceuticals, Inc. has a price-to-sales ratio of 8.72x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue